IDEAYA BIOSCIENCES INC
Biopharmaceutical company focused on precision oncology through the discovery, development and commercialization of targeted therapies
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IDEAYA Biosciences stock with a target price of $53.9, indicating strong growth potential.
Financial Health
IDEAYA Biosciences is generating modest revenue and cash flow, but its financial position shows room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IDYA
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: June 17, 2025
Explore BasketPersonalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Published: June 17, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Pipeline Watch
Trial readouts and regulatory milestones strongly influence valuation, so keep an eye on upcoming clinical data — though results can be binary and volatile.
Synthetic Lethality Focus
IDEAYA's scientific approach targets cancer-specific genetic vulnerabilities, which may offer selective treatments but depends on complex biology translating to patients.
Partnering Potential
Collaborations with larger pharma can de‑risk development and expand resources, yet they typically hinge on compelling clinical progress and commercial viability.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
